Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke.

ABSTRACT:

Objectives

To evaluate the quality of preclinical evidence for mesenchymal stromal cell (MSC) treatment of ischemic stroke, determine effect size of MSC therapy, and identify clinical measures that correlate with differences in MSC effects.

Methods

A literature search identified studies of MSCs in animal models of cerebral ischemia. For each, a Quality Score was derived, and effect size of MSCs was determined for the most common behavioral and histologic endpoints.

Results

Of 46 studies, 44 reported that MSCs significantly improved outcome. The median Quality Score was 5.5 (of 10). The median effect size was 1.78 for modified Neurological Severity Score, 1.73 for the adhesive removal test, 1.02 for the rotarod test, and 0.93 for infarct volume reduction. Quality Score

SUBMITTER: Vu Q 

PROVIDER: S-EPMC4001201 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature